IRIS
GIAMPIERI, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.205
AS - Asia 3.547
EU - Europa 3.437
SA - Sud America 911
AF - Africa 257
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 16.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.062
SG - Singapore 1.170
BR - Brasile 729
VN - Vietnam 722
CN - Cina 638
RU - Federazione Russa 611
IT - Italia 513
UA - Ucraina 431
DE - Germania 325
SE - Svezia 324
IE - Irlanda 309
HK - Hong Kong 305
TR - Turchia 217
FR - Francia 216
FI - Finlandia 195
GB - Regno Unito 164
DK - Danimarca 152
IN - India 114
CI - Costa d'Avorio 99
KR - Corea 84
AR - Argentina 68
CA - Canada 64
BD - Bangladesh 60
MA - Marocco 56
MX - Messico 51
ZA - Sudafrica 49
JP - Giappone 45
NL - Olanda 43
IQ - Iraq 37
PL - Polonia 36
ES - Italia 31
CO - Colombia 30
EC - Ecuador 28
ID - Indonesia 27
VE - Venezuela 20
BE - Belgio 18
MY - Malesia 18
PK - Pakistan 14
UZ - Uzbekistan 14
CL - Cile 13
AT - Austria 12
AZ - Azerbaigian 12
TH - Thailandia 11
TN - Tunisia 11
DZ - Algeria 10
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
KE - Kenya 8
PH - Filippine 8
PY - Paraguay 8
EG - Egitto 7
LT - Lituania 7
PE - Perù 7
RS - Serbia 7
SK - Slovacchia (Repubblica Slovacca) 6
TW - Taiwan 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
ET - Etiopia 5
EU - Europa 5
HN - Honduras 5
PA - Panama 5
RO - Romania 5
AU - Australia 4
BH - Bahrain 4
IL - Israele 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
AL - Albania 3
AO - Angola 3
JM - Giamaica 3
PT - Portogallo 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HR - Croazia 2
LB - Libano 2
MD - Moldavia 2
MK - Macedonia 2
NG - Nigeria 2
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
IR - Iran 1
LK - Sri Lanka 1
LV - Lettonia 1
MM - Myanmar 1
MR - Mauritania 1
Totale 16.356
Salva come PNG Salva come JPEG
Città #
Ashburn 1.563
Singapore 790
Chandler 624
Fairfield 496
Jacksonville 468
San Jose 408
Des Moines 352
Dallas 329
Dublin 304
Hong Kong 293
Boardman 288
Wilmington 261
New York 251
Ho Chi Minh City 230
Woodbridge 227
Seattle 195
Houston 185
Beijing 183
Hanoi 181
The Dalles 164
Ann Arbor 159
Los Angeles 149
Cambridge 148
Lauterbourg 113
Lawrence 113
Princeton 113
Centro 105
Moscow 104
San Mateo 104
Abidjan 98
Munich 90
Turku 70
Turin 66
São Paulo 55
Buffalo 54
Hefei 54
Orem 49
Helsinki 48
San Diego 48
London 46
Santa Clara 45
Chicago 43
Chennai 35
Tokyo 35
Ancona 33
Washington 33
Johannesburg 32
Warsaw 31
Montreal 29
Denver 28
Haiphong 28
Atlanta 27
Da Nang 27
Pune 25
Amsterdam 24
Frankfurt am Main 23
Stockholm 22
Brooklyn 21
Rio de Janeiro 21
Porto Alegre 20
Columbus 18
Guangzhou 18
Council Bluffs 17
Manchester 17
Rome 17
Toronto 17
Wuhan 17
Brussels 16
Poplar 16
Mexico City 15
Brasília 14
Hải Dương 14
Shanghai 14
Belo Horizonte 13
Campinas 13
New Delhi 13
Nuremberg 13
Baghdad 12
Baku 12
Cagliari 12
Curitiba 12
Norwalk 12
Paris 12
Tashkent 12
Thái Nguyên 12
Guayaquil 11
Izmir 11
Salvador 11
Biên Hòa 10
Boston 10
Can Tho 10
Elk Grove Village 10
Phoenix 10
Bangkok 9
Bến Tre 9
Fortaleza 9
Jakarta 9
Kilburn 9
Milan 9
Mumbai 9
Totale 10.664
Salva come PNG Salva come JPEG
Nome #
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 212
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 210
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 199
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 197
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 194
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 193
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 190
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 190
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 187
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 186
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 185
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 181
Optimal management of resected gastric cancer 179
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 179
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 174
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 173
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 169
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 169
5-Fluorouracil pharmacogenomics: still rocking after all these years? 166
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 166
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 164
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 161
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 160
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab 157
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 153
Adjuvant treatment after surgical resection 153
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 152
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 152
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 149
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy 148
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 147
BRAF-mutant colorectal cancer, a different breed evolving 147
Benefits and limitations of a multidisciplinary approach in cancer patient management 146
Panitumumab for the treatment of metastatic colorectal cancer: A review 144
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 144
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 143
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 143
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 142
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 142
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 142
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 140
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 140
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 140
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 139
Trattamento del carcinoma del pancreas. Attualità e prospettive 139
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 138
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 138
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 138
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 137
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 137
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 134
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 134
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 134
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 133
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase 133
New Insights into Hormonal Therapies in Uterine Sarcomas 132
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 131
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 130
Novel perspectives for the treatment of gastric cancer: From a global approach to a personalized strategy 129
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study 128
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 128
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study 128
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 128
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 127
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 127
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 127
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 126
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 126
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 123
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 123
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 123
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 123
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 123
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 122
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 122
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 120
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 120
BRCA mutations and gastrointestinal cancers: When to expect the unexpected? 118
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 116
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 115
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 112
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab 112
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 112
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? 110
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 110
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 109
Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: biological and clinical implications 108
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 108
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. 107
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 107
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 106
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 105
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 104
Gastric cancer: Therapeutic choices in advanced disease 104
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. 103
Selecting the best treatment for an individual patient. 103
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study 103
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan 102
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 101
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 100
Totale 13.983
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.414
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.414
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021450 0 0 0 0 0 0 0 0 0 197 150 103
2021/2022896 74 200 20 19 6 60 34 58 62 112 92 159
2022/20232.081 132 250 137 140 120 512 1 99 436 24 192 38
2023/20241.154 175 25 99 131 164 315 12 41 2 26 19 145
2024/20252.446 315 190 62 41 125 100 241 92 455 212 302 311
2025/20266.681 492 521 416 822 926 531 1.184 652 572 565 0 0
Totale 16.641